New obesity label unlikely to prompt marketing overhaul

07/15/2013 | Medical Marketing & Media

The American Medical Association's designation of obesity as a disease will raise awareness, but it will not result in significant marketing changes, executives at drugmakers Vivus and Arena say. Vivus, which makes anti-obesity drug Qsymia, will incorporate the AMA's stance into promotional material but plan no immediate changes to direct-to-consumer advertising. Nonetheless, the designation will be a conversation starter for doctors and patients, and the sector is likely to follow the same path as antidepressants, Orexigen Chief Commercial Officer Mark Booth says.

View Full Article in:

Medical Marketing & Media

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Deputy Director, Marketing
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Director of Operations - GBS
Mayo Clinic
MN
Director of Actuarial Services, Government Programs
PacificSource
OR
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC